Log in
Enquire now
Acorda Therapeutics

Acorda Therapeutics

Acorda is a biotechnology company founded in 1995 by Ron Cohen and headquartered in Ardsley, New York developing and commercializing neurology therapies for Parkinson's disease, migraines, and multiple sclerosis.

OverviewStructured DataIssuesContributors

Contents

acorda.com
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Healthcare
Healthcare
Pharmaceutical industry
Pharmaceutical industry
Therapeutics
Therapeutics
Biomedical engineering
Biomedical engineering
Biopharmaceutical
Biopharmaceutical
Technology
Technology
...
Location
Waltham, Massachusetts
Waltham, Massachusetts
0
Ardsley, New York
Ardsley, New York
‌
Pearl River, New York
0
United States
United States
B2X
B2B
B2B
0
B2C
B2C
CEO
‌
Ron Cohen
Founder
‌
Ron Cohen
AngelList URL
angel.co/acorda-therapeutics
Date Incorporated
1995
Number of Employees (Ranges)
201 – 5000
Email Address
info@acorda.com0
Phone Number
+178124226770
+191434743000
Full Address
420 Saw Mill River Road, Ardsley, NY United States 105020
283 Bear Hill Road, Waltham, MA United States 024510
2 Blue Hill Plaza, 3rd Floor Pearl River, NY United States 109650
CIK Number
1,008,8480
Investors
Cross Atlantic Partners
Cross Atlantic Partners
Easton Capital
Easton Capital
Forward Ventures
Forward Ventures
Ridgeback Capital
Ridgeback Capital
Founded Date
1995
Fax Number
617-884-39900
914-347-45600
Total Funding Amount (USD)
53,200,000
Stock Symbol
ACOR0
Exchange
Nasdaq
Nasdaq
0
Glassdoor ID
26857
Latest Funding Type
Series A
Series A
Legal Entity Identifier
5493007NPB5YRM8QGL530
Wellfound ID
acorda-therapeutics
Country
United States
United States
Headquarters
Ardsley, New York
Ardsley, New York

Other attributes

Company Operating Status
Active
SIC Code
2,8360
Wikidata ID
Q4674531

Acroda Therapeutics is a biotechnology company based out of Ardsley, New York that was founded in 1995 by Ron Cohen. The company is working to develop and commercialize treatments for neurological disorders of the central nervous system such as multiple sclerosis, spinal cord injuries, and Parkinson's disease.

Acquisitions
Biotie Therapies

On January 19, 2016 Acorda Therapeutics acquired Biotie Therapies for $25.60 per share for a total of approximately $363 million. Acorda Therapeutics bought Biotie Therapies to acquire two of its drug candidates for the treatment of Parkinson's disease called Tozadenant and SYN120.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

Acorda Therapeutics investor calls for company to explore sale

Greg Roumeliotis

https://www.reuters.com/article/us-acordatherapeutics-scopiacpital-idUSKBN1AN1FV

News

Acorda Therapeutics stock rises on closure of FDA inspections

Uttara Choudhury

https://ca.proactiveinvestors.com/companies/news/207402/acorda-therapeutics-stock-rises-on-closure-of-fda-inspections-207402.html

Web

What's Behind Acorda Therapeutics Crashing 24.5% Today -- The Motley Fool

Todd Campbell

https://www.fool.com/investing/2018/09/10/whats-behind-acorda-therapeutics-crashing-245-toda.aspx

News

References

Find more companies like Acorda Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.